
BIOR Stock Forecast & Price Target
BIOR Analyst Ratings
Bulls say
Biora Therapeutics Inc is positioned for growth due to anticipated increases in business development and collaboration activities, which could bolster its program advancements. The introduction of the smaller BioJet device enhances usability, potentially leading to greater market penetration and a wider range of suitable therapeutic molecules. Furthermore, positive results from the BT-600 Phase 1 trial and ongoing progress with the NaviCap device support a favorable outlook regarding clinical success and potential expansion of Biora's asset portfolio.
Bears say
Biora Therapeutics Inc. faces substantial risks that negatively impact its financial outlook, primarily due to potential failures or inconclusive results from its clinical trials, particularly concerning its BT-600 program and the NaviCap platform. Additionally, the company struggles with securing sufficient funding to advance its product development, which could lead to further dilutive capital raises. Compounding these issues is the significant amount of convertible debt on Biora's balance sheet, posing considerable dilutive risk over the next several years.
This aggregate rating is based on analysts' research of Biora Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
BIOR Analyst Forecast & Price Prediction
Start investing in BIOR
Order type
Buy in
Order amount
Est. shares
0 shares